SILVER SPRING, Md.—The U.S. Food and Drug Administration may review the impact of LASIK eye surgery on improving consumers’ lives, a senior FDA official reportedly said this week.

Daniel Schultz, MD, director of FDA’s Center for Devices and Radiological Health, was quoted as saying several concerns have been raised regarding patient satisfaction with the LASIK (laser-assisted in situ keratomileusis) vision correction procedure. He said an FDA advisory panel is likely to hold a public meeting to discuss the issue. That meeting, reportedly to be held as early as next month, would focus on patients’ quality of life after LASIK surgery.

Last July, the FDA responded to an individual’s requests for a halt to the procedures and withdrawal of their FDA approval. The agency said then that the devices were safe and effective, but that advisory-panel discussions “could complement” its other safety monitoring.

The laser procedure was approved by the FDA in the mid-1990s.